Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT06010667
A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Sponsor: Hebei Medical University Fourth Hospital
View on ClinicalTrials.gov
Summary
The primary objective of this study is to evaluate the efficacy and safety of cyclophosphamide and bevacizumab in combination with Envafolimab in the treatment of recurrent epithelial ovarian cancer (EOC), fallopian tube cancer, and primary peritoneal cancer.
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2023-09-01
Completion Date
2026-08-01
Last Updated
2023-08-24
Healthy Volunteers
No
Conditions
Interventions
DRUG
Envafolimab
With or without Envafolimab
Locations (1)
Hebei
Shijiazhuang, Hebei, China